Ivonescimab Combined With Chemotherapy for the Treatment of Leptomeningeal Metastases Failed to EGFR-TKIs

Inclusion criteria

• Age range: 18-75y
• EGFR mutation NSCLC
• LM was diagnosed through head enhanced MRI or (and) CSF cytology
• EGFR activation mutations were positive
• Patients who have failed to first or second-generation EGFR-TKI treatment，without T790M mutation; or failed to third-generation EGFR-TKI treatment
• Hematological, coagulation, renal and liver function is sufficient
• Women of childbearing age must undergo a pregnancy test and the result must be negative

Exclusion criteria

• Patients with squamous cell carcinoma, large cell carcinoma, mixed cell lung cancer
• The patient has other driver genes that can be treated with targeted drugs
• Subjects who have previously received immunotherapy with a discontinuation time of less than 3 months
• Received EGFR-TKI treatment within one week prior to the first administration
• Received non-specific immunomodulatory therapy
• Clinical manifestations of neurological failure
• Non malignant neurological disorders
• Radiotherapy for the chest and whole brain should be completed within 4 weeks before enrollment
• Tumor surrounded important blood vessels or had obvious necrosis or cavities
• Tumor has invaded important surrounding organs and blood vessels
• History of severe bleeding tendency or coagulation dysfunction
• The risk of developing esophagotracheal fistula or esophageal pleural fistula